Tests TRIV-573 for moderate to severe atopic dermatitis in adults
Tests whether TRIV-573 injections help adults with moderate to severe eczema.
Plain-language title generated from the registry record
Registry title: A Study Evaluating TRIV-573 in Atopic Dermatitis
Key facts
- Where
- Ivano-Frankivsk and Kyiv, UkraineSee the 2 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderate to severe, active atopic dermatitis. Some will get TRIV-573 and some will get a placebo.
- Age
- 18 Years to 75 Years
- Sex
- All sexes can join.
- Disease stage
- Moderate to severe, active and symptomatic atopic dermatitis.
- Earlier treatment
- People who used prohibited medications within the stated washout periods cannot join.
Main reasons for not taking part
- Severe or uncontrolled medical conditions
- Use of prohibited medications within stated washout periods
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07782333, who can take part
Where in Ukraine
- Ivano-FrankivskHospital not named in the registryContact: Study DirectorTaking people
- KyivHospital not named in the registryContact: Study DirectorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Triveni Bio
- Trial code
- NCT07782333
- Record updated
- 28 October 2026
- Original description
The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573.Read full original descriptionShow less
A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Multiple Subcutaneous Doses of TRIV-573 in Participants With Moderate to Severe Atopic Dermatitis
The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573.
Participants will receive 5 doses of the study intervention that they are randomized to (TRIV-573 or placebo).
The study duration for individual participants is up to 40 weeks, including a Screening period of up to 30 days.
Inclusion: Has Atopic Dermatitis; Has moderate to severe, active and symptomatic atopic dermatitis.
Exclusion: Use of prohibited medications within stated washout periods; Severe or uncontrolled medical conditions.